ValuEngine upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a sell rating to a hold rating in a research report released on Friday.

FATE has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Fate Therapeutics from a hold rating to a buy rating and set a $4.75 target price for the company in a research report on Friday, September 8th. Raymond James Financial reiterated a buy rating on shares of Fate Therapeutics in a research report on Tuesday, December 12th. Leerink Swann reiterated an outperform rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Friday, September 8th. BMO Capital Markets reiterated a buy rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Thursday, November 2nd. Finally, Piper Jaffray Companies started coverage on shares of Fate Therapeutics in a research report on Monday, December 18th. They set an overweight rating and a $10.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $7.25.

Shares of Fate Therapeutics (FATE) opened at $5.61 on Friday. Fate Therapeutics has a 1-year low of $2.40 and a 1-year high of $5.87. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32. The stock has a market cap of $286.01, a PE ratio of -5.97 and a beta of 1.52.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The company’s revenue was up .0% compared to the same quarter last year. analysts forecast that Fate Therapeutics will post -0.99 EPS for the current fiscal year.

In other news, insider Daniel D. Shoemaker sold 13,225 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $3.87, for a total value of $51,180.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Cindy Tahl sold 8,091 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $3.85, for a total transaction of $31,150.35. The disclosure for this sale can be found here. 10.88% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund purchased a new stake in Fate Therapeutics in the second quarter valued at approximately $131,000. Rhumbline Advisers purchased a new stake in Fate Therapeutics in the second quarter valued at approximately $133,000. Hochman Cole Investment Advisors Inc. purchased a new stake in Fate Therapeutics in the third quarter valued at approximately $158,000. Schwab Charles Investment Management Inc. purchased a new stake in Fate Therapeutics in the second quarter valued at approximately $214,000. Finally, California State Teachers Retirement System purchased a new stake in Fate Therapeutics in the second quarter valued at approximately $219,000. Institutional investors own 49.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/12/26/fate-therapeutics-fate-raised-to-hold-at-valuengine.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.